Clinical Pregnancies After Cryopreservation of Donor Oocytes With an Open or Closed Device

Sponsor
Universitair Ziekenhuis Brussel (Other)
Overall Status
Terminated
CT.gov ID
NCT02940106
Collaborator
(none)
19
1
2
21
0.9

Study Details

Study Description

Brief Summary

This randomized pilot study will assess if there is a difference in clinical pregnancies using donor oocytes cryopreserved in either a closed or a semi-closed vitrification device.

Condition or Disease Intervention/Treatment Phase
  • Device: Cryotop device
  • Device: CBSvit device
N/A

Detailed Description

Oocyte cryopreservation was optimized by the use of a new technique: vitrification. Vitrification can be performed using either open devices (where the oocytes are in direct contact with the liquid nitrogen) or closed systems (where the oocytes are never in contact with liquid nitrogen). Previous studies have associated the use of open devices to higher oocyte survival rates and better embryo development. However, any beneficial effect on clinical pregnancy rates is yet to be proven. Hence, the objective of this study is to compare the clinical pregnancy rates of open and closed oocyte vitrification devices.

Study Design

Study Type:
Interventional
Actual Enrollment :
19 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
Investigation of the Clinical Pregnancies Obtained After Cryopreservation of Donor Oocytes With an Open or Closed Device
Actual Study Start Date :
Oct 1, 2016
Actual Primary Completion Date :
Jul 1, 2018
Actual Study Completion Date :
Jul 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: closed device

Standard cryopreservation system.

Device: CBSvit device
a different device for oocyte vitrification (with a lower cooling rate)
Other Names:
  • CBSvit closed vitrification device (CryoBioSystems vitrification device)
  • Active Comparator: open device

    New cryopreservation system.

    Device: Cryotop device
    a different device for oocyte vitrification (with a very high cooling rate)
    Other Names:
  • Cryotop open vitrification device (Kitazato)
  • Outcome Measures

    Primary Outcome Measures

    1. Clinical pregnancy [7 weeks]

      Pregnancy determined by ultrasound

    Secondary Outcome Measures

    1. survival [1 week]

      oocyte survival post-warming based on the morphological appearance of the oocytes immediately after warming: degenerated oocytes are non-surviving oocytes; oocytes with a normal morphological appearance are surviving oocytes

    2. fertilization [1 week]

      oocyte fertilization post-insemination: the day after oocyte insemination fertilization is checked: if one male and one female pronucleus appear, the oocyte is fertilized. if both nuclei are not present or more nuclei are present, the oocyte is considered not fertilized.

    3. embryo development [2 weeks]

      embryo development post-fertilization: on day 3 of pre-implantation development, the embryo is scored for the number of cells, fragmentation, appearance of nuclei and other embryological parameters: based on these parameters, an embryological score is given to the embryo. On day 5 of development (blastocyst stage) another score is given to the embryo based on the appearance of the trophectoderm and inner cell mass cells.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 47 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • this is a pragmatic randomized clinical trial. Hence, all consenting oocyte recipients will be eligible for the study
    Exclusion Criteria:
    • women who do not consent or that cannot comprehend the investigational nature of the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Universitair Ziekenhuis Brussel Brussels Belgium 1090

    Sponsors and Collaborators

    • Universitair Ziekenhuis Brussel

    Investigators

    • Principal Investigator: Neelke De Munck, MSc., Universitair Ziekenhuis Brussel

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Neelke De Munck, Master in Science, Universitair Ziekenhuis Brussel
    ClinicalTrials.gov Identifier:
    NCT02940106
    Other Study ID Numbers:
    • 2016/245
    First Posted:
    Oct 20, 2016
    Last Update Posted:
    Jan 26, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Keywords provided by Neelke De Munck, Master in Science, Universitair Ziekenhuis Brussel
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 26, 2022